Moberg Pharma AB has entered into an exclusive licensing agreement with Karo Healthcare AB for the commercialization of MOB-015 (Terclara) in 19 European markets. The agreement enables a coordinated launch across all major EU countries and the United Kingdom under the globally recognized antifungal brand, Lamisil. Karo Healthcare will handle marketing, distribution, and sales across Europe, while Moberg Pharma will receive royalties and compensation for product supply.

MOB-015, developed by Moberg Pharma, is a next-generation topical formulation of terbinafine, the active ingredient in Lamisil. It addresses the limitations of oral antifungal treatments, which carry risks such as drug interactions and liver toxicity. In clinical studies, MOB-015 achieved mycological cure rates comparable to oral therapy, with 76 percent of patients showing complete fungal clearance.

Moberg Pharma CEO Anna Ljung stated that launching the product under the trusted Lamisil brand provides a unique opportunity to expand its leadership in antifungal treatments beyond Sweden and Norway. Karo Healthcare CEO Christoffer Lorenzen highlighted the collaboration as a blend of strong science and commercial expertise.

The partnership strengthens both companies’ positions in Europe’s antifungal market and marks a major milestone in Moberg Pharma’s global expansion strategy.